Darbepoetin alfa (Aranesp)
Darbepoetin alfa
Amgen south africa (pty)ltd
Registration
- Applicant
- Amgen south africa (pty)ltd
- Registrations
- 12
- Schedule source
- Consolidated Schedules 06 July 2026
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Aranesp 10 ug EACH O,4 ml SOLUTION CONTAINS DARBEPOETIN ALFA 10,0 ug | 10 ug | 41088441/8.3/0884 | Registered | S4 | None |
| Aranesp 15 ug EACH O,375 ml SOLUTION CONTAINS DARBEPOETIN ALFA 15,0 ug | 15 ug | 41088541/8.3/0885 | Registered | S4 | None |
| Aranesp 20 ug EACH O,5 ml SOLUTION CONTAINS DARBEPOETIN ALFA 20,0 ug | 20 ug | 41088641/8.3/0886 | Registered | S4 | None |
| Aranesp 30 ug EACH O,3 ml SOLUTION CONTAINS DARBEPOETIN ALFA 30,0 ug | 30 ug | 41088741/8.3/0887 | Registered | S4 | None |
| Aranesp 40 ug EACH O,4 ml SOLUTION CONTAINS DARBEPOETIN ALFA 40,0 ug | 40 ug | 41088841/8.3/0888 | Registered | S4 | None |
| Aranesp 50 ug EACH O,5 ml SOLUTION CONTAINS DARBEPOETIN ALFA 50,0 ug | 50 ug | 41088941/8.3/0889 | Registered | S4 | None |
| Aranesp 60 ug EACH O,3 ml SOLUTION CONTAINS DARBEPOETIN ALFA 60,0 ug | 60 ug | 41089041/8.3/0890 | Registered | S4 | None |
| Aranesp 80 ug EACH O,4 ml SOLUTION CONTAINS DARBEPOETIN ALFA 80,0 ug | 80 ug | 41089141/8.3/0891 | Registered | S4 | None |
| Aranesp 100 ug EACH O,5 ml SOLUTION CONTAINS DARBEPOETIN ALFA 100,0 ug | 100 ug | 41089241/8.3/0892 | Registered | S4 | None |
| Aranesp 150 ug EACH O,3 ml SOLUTION CONTAINS DARBEPOETIN ALFA 150,0 ug | 150 ug | 41089341/8.3/0893 | Registered | S4 | None |
| Aranesp 300 ug EACH O,6 ml SOLUTION CONTAINS DARBEPOETIN ALFA 300,0 ug | 300 ug | 41089441/8.3/0894 | Registered | S4 | None |
| Aranesp 500 ug EACH 1,O ml SOLUTION CONTAINS DARBEPOETIN ALFA 500,0 ug | 500 ug | 41089541/8.3/0895 | Registered | S4 | None |
Regulatory status
Where S4 sits on the scale
Prescription-only medicine.
Schedule 4 covers most ordinary prescription medicines. You need a prescription from an authorised prescriber, such as a doctor or dentist, and a pharmacist dispenses it. Its price, name, pack size and strength can still be told to the public, as long as nothing links it to what it treats.
Schedule S4, matched to the Consolidated Schedules by ingredient, confidence high.
Who may supply: A pharmacist dispensing against a written or verbal prescription from an authorised prescriber; a veterinarian, who may also prescribe, compound or dispense it directly; a medical practitioner or dentist, who may prescribe it and may compound or dispense it directly only if licensed under section 22C(1)(a); manufacturers and wholesalers may supply people who may lawfully possess it; and, for animal treatment, a person practising a para-veterinary profession, on a veterinarian's written or verbal instruction.
Consolidated Schedules listings for Darbepoetin alfa
S4: Darbepoetin alfa
Consolidated Schedules 06 July 2026, line 5952
Pharmacological class: Erythropoietics (haematinics). (class 8.3)
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
No structure available
This product's active ingredient could not be matched to a single known compound.
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.